Dr. Giaccone on Treatment Options in NSCLC
Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.
Related Articles
Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology
Abdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.
Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCL
Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.
ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Revisit Every OncLive On Air Episode from March 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer…
Nivolumab plus Ipilimumab vs Chemotherapy as First-line Treatment for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: First Results of the CheckMate 8HW Study
In his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for…
Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study
A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.